Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test aims to detect tumor DNA without biopsy

NCT ID NCT07868640

Diagnosis Sponsor: Grand Hôpital de Charleroi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 09, 2026 · Last updated Oct 09, 2026

Summary

Researchers at the Grand Hôpital de Charleroi are validating a molecular test called TST79 that looks for circulating tumor DNA in blood plasma. The study enrolls 15 patients with various cancers, including lung, colorectal, breast, prostate, melanoma, and others, who are undergoing cancer treatment. By comparing blood samples to standard tumor tissue analysis, the team aims to confirm the test can reliably detect cancer mutations from a simple blood draw.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TST79 molecular test on blood plasma
What this could lead to
If validated, the TST79 test could give doctors a less invasive way to track tumor mutations through a simple blood draw, potentially guiding treatment decisions without repeated tissue biopsies.
What could go wrong
This is a small validation study of 15 patients at a single hospital, so the test may not perform reliably across different cancer types or in larger, more diverse groups. The approach also depends on tumors shedding enough DNA into the blood to be detected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with the following types of cancer may be invited to donate blood as part of one of two approaches: * lung adenocarcinoma * colorectal adenocarcinoma * breast carcinoma * prostate adenocarcinoma * clear cell renal cell carcinoma * GIST/gastrointestinal stromal tumour * melanoma * urothelial carcinoma * endometrial carcinoma * high-grade ovarian carcinoma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma cancer colorectal adenocarcinoma endometrial carcinoma gastrointestinal stromal tumor lung adenocarcinoma melanoma neoplasm nonpapillary renal cell carcinoma prostate adenocarcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Grand Hôpital de Charleroi

    RECRUITING

    Charleroi, Hainaut, 6060, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.